Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer.
Open Access
- 1 June 1998
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 133 (6) , 647-651
- https://doi.org/10.1001/archsurg.133.6.647
Abstract
FOLLOWING SURGICAL management of primary breast cancer, systemic adjuvant therapy is indicated for patients with axillary metastases but also is increasingly recommended for those without histological evidence of axillary node involvement.1-3 Because of this trend to use systemic adjuvant therapy regardless of lymph node status and because of the direct relationship between the incidence of axillary metastasis and the size of the primary tumor,4,5 recent reports have questioned the benefit of routine level I and II axillary lymph node dissection (ALND) in patients with T1 primary breast cancers, particularly T1a and T1b lesions.6,7Keywords
This publication has 1 reference indexed in Scilit: